Lucile Bauguion

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

M. Ychou, E. Assenat, J. Biagi, 2022, JAMA oncology.

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

N. Rioux-Leclercq, F. Beuvon, A. Lièvre, 2022, Clinics and research in hepatology and gastroenterology.

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

T. Conroy, O. Bouché, P. Hammel, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prognostic factors associated with upper gastrointestinal bleeding based on the French multicenter SANGHRIA trial

D. Heresbach, L. Tsakiris, Margot Laly, 2021, Endoscopy International Open.

Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.

G. Prager, J. Taïeb, T. Mazard, 2023, European journal of cancer.

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.

C. Neuzillet, F. Desseigne, B. Chibaudel, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.